Answers are grounded in this paper and cite their sources.
From the Department of Ophthalmology, University Hospital Ayr, Ayr, Scotland, United Kingdom (Srinivasan); University of West of Scotland, Ayr, Scotland, United Kingdom (Srinivasan); Munich, Germany (Dresp). Corresponding author: Sathish Srinivasan, FRCSEd, FRCOphth, FACS, Department of Ophthalmology, 3rd Floor, University Hospital Ayr, Dalmellington Rd, Ayr, KA6 DX Scotland, United Kingdom. Email: [email protected]. Submitted: October 12, 2022 | Accepted: October 18, 2022 Disclosures: J.H. Dresp has served as a consultant for Bausch & Lomb, Inc., Chauvin, Croma Pharma GmbH, D.O.R.C. International BV, HumanOptics AG, Hyaltech, i.com medical, Johnson & Johnson Vision, LensGen, MIRO, Pharmpur, Second Sight, Théa Pharma GmbH, Technolas Perfect Vision, Valeant in regulatory affairs, quality management, research and development. S. Srinivasan serves as the medical advisory board member for Dutch Ophthalmic Research Institute. First author:Sathish Srinivasan, FRCSEd, FRCOphth, FACSDepartment of Ophthalmology, University Hospital Ayr, Ayr, Scotland, United Kingdom
No takes yet. Share an insight, caveat, or question.
Srinivasan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: